Clinical Study on Qilong Capsule Combined with Oxiracetam in the Treatment of Mild Cognitive Impairment after Cerebral Infarction

WEI Jianhui; GAO Li; LI Meng; LUO Xiaojing; XING Lin

doi:10.3639/i.issn.2095-3097.2024.10.045

Abstract：Objective To explore the clinical efficacy of Qilong Capsule combined with Oxiracetam in the treatment of mild cognitive impairment(MCI)after cerebral infarction,and to provide a treatment direction for the clinical application of integrated traditional Chinese and Western medicine.Methods A total of 186 patients with MCI after cerebral infarction who were admitted to Baoji Central Hospital from July 2022 to June 2024 were included and randomly divided into two groups with 93 patients in each group using the random number method.One group was designated as the control group,and the other was the combination group.The control group received Oxiracetam capsules,while the combination group received both Oxiracetam capsules and Qilong Capsules.Both groups underwent treatment for 2 months.The cognitive impairment of the two groups of patients was evaluated before and after treatment.The levels of brain-derived neurotrophic factor(BDNF),neuron-specific enolase(NSE),calcitonin(PCT),C-reactive protein(CRP)in serum,as well as plasma viscosity(PV)and hematocrit(PCV)in blood were compared between the two groups before and after treatment.Moreover,the clinical efficacy,occurrence and recurrence of adverse reactions of the two groups after treatment were also compared.Results Before treatment,there was no significant difference in the General Practitioner Assessment of Cognition(GPCOG),Montreal Cognitive Assessment(MoCA),and Barthel Index(BI)scores between the two groups(P＞0.05).After treatment,GPCOG,MoCA,and Instrumental Activities of Daily Living(IADL)scores in both groups were significantly higher than their respective baseline scores(P＜0.05),and the GPCOG,MoCA,and BI scores in the combination group were significantly higher than those in the control group(P＜0.05).Before treatment,there were no significant differences in serum levels of BDNF,NSE,PCT,CRP,PV,PCV between the two groups(P＞0.05).After treatment,the serum BDNF level in the combination group was significantly higher than that in the control group(P＜0.05),while the levels of NSE,PCT,CRP,PV,and PCV were significantly lower in the combination group than in the control group(P＜0.05).The total effective rate in the combination group was significantly higher than that in the control group(x2=6.226,P=0.013).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).The recurrence rate in the combination group was significantly lower than that in the control group(P＜0.05).Conclusion The combination of Qilong Capsule and Oxiracetam has a significant effect in the treatment of mild cognitive impairment after cerebral infarction,with good safety and a low recurrence rate.